Clinical trial · Observational
Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma
Deciphering the Role of Circular RNAs in the Pathogenesis and Therapy Resistance of ALKpositive Anaplastic Large-cell Lymphoma
NCT05934045CI-TRIAL-00067808CIRComaunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of thE project is to determine, whether circRNAs could be used as circulating prognostic and/or predictive biomarkers of ALK+ ALCL resistance to treatment and whether they can be exploited as therapeutic targets.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| ALK-Positive Anaplastic Large Cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| RNAseq | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- ALCL patient samples (serum)
- description
- serum collected at diagnosis, during treatment and/or at relapse
- interventionNames
- Biological: RNAseq
Primary outcomes (1)
- measure
- Number of participants with relapse and circulating circRNA
- timeFrame
- 1 year after the end of treatment
- description
- RNAseq analysis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * patient at diagnosis of ALK+ ALCL * patient at the time of relapse for ALK+ ALCL * patient without ALK+ ALCL Exclusion Criteria: \-
References
Publications (0)
Data not yet available
No reference posted for this study.